|
1
|
Ostrakhovitch EA, Song ES, Stegemann JE, McLeod M, Yamasaki TR. Effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability. Sci Rep 2025; 15:15597. [PMID: 40320462 PMCID: PMC12050307 DOI: 10.1038/s41598-025-99794-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2024] [Accepted: 04/23/2025] [Indexed: 05/08/2025] Open
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized by nigrostriatal degeneration and aggregation of α-synuclein (α-Syn) with accumulation of insoluble aggregates in Lewy bodies. Familial mutations in α-Syn are associated with the development of PD. Accumulation of insoluble aggregates results in neuronal toxicity. Identification of compounds that inhibit seeding activity of α-Syn is of great importance. Here we investigate the potential of H2S donor, sodium hydrosulfide (NaHS), to inhibit α-Syn aggregation. We examined the effect of NaHS on fibril growth kinetics and the structural change of α-Syn fibrils formed by self-seeding and cross-seeding of wild-type (wt) and PD familial α-Syn mutations. NaHS slowed both self- and cross-seeded A53T α-Syn fibril formation but not wild-type fibril formation. We observed a decrease in the formed fibril length in vitro. We examined the effect on fibril formation within cells. NaHS significantly reduced the number and filament length of formed oligomers in an α-Syn overexpressing cell model. Furthermore, NaHS rescued viability of A53T α-Syn overexpressing cells seeded with wt- and mutant preformed fibrils. These results support a conformation-specific effect of hydrogen sulfide on alpha-synuclein aggregation and cell viability which deserves further exploration for therapeutic potential.
Collapse
Affiliation(s)
- Elena A Ostrakhovitch
- Department of Neurology, University of Kentucky, 740 South Limestone St., Ste. J401, Lexington, KY, 40536-0284, USA
- Veterans Affairs, Lexington, KY, 40536, USA
| | - Eun-Suk Song
- Department of Neurology, University of Kentucky, 740 South Limestone St., Ste. J401, Lexington, KY, 40536-0284, USA
- Veterans Affairs, Lexington, KY, 40536, USA
| | - Johannah E Stegemann
- Department of Neurology, University of Kentucky, 740 South Limestone St., Ste. J401, Lexington, KY, 40536-0284, USA
- Veterans Affairs, Lexington, KY, 40536, USA
| | - Michael McLeod
- Department of Neurology, University of Kentucky, 740 South Limestone St., Ste. J401, Lexington, KY, 40536-0284, USA
| | - Tritia R Yamasaki
- Department of Neurology, University of Kentucky, 740 South Limestone St., Ste. J401, Lexington, KY, 40536-0284, USA.
- Veterans Affairs, Lexington, KY, 40536, USA.
| |
Collapse
|
|
2
|
Bétemps D, Arsac JN, Nicot S, Canal D, Tlili H, Belondrade M, Morignat E, Verchère J, Gaillard D, Bruyère-Ostells L, Mayran C, Lakhdar L, Bougard D, Baron T. Protease-Sensitive and -Resistant Forms of Human and Murine Alpha-Synucleins in Distinct Brain Regions of Transgenic Mice (M83) Expressing the Human Mutated A53T Protein. Biomolecules 2023; 13:1788. [PMID: 38136658 PMCID: PMC10741842 DOI: 10.3390/biom13121788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/06/2023] [Accepted: 12/07/2023] [Indexed: 12/24/2023] Open
Abstract
Human neurodegenerative diseases associated with the misfolding of the alpha-synuclein (aS) protein (synucleinopathies) are similar to prion diseases to the extent that lesions are spread by similar molecular mechanisms. In a transgenic mouse model (M83) overexpressing a mutated (A53T) form of human aS, we had previously found that Protein Misfolding Cyclic Amplification (PMCA) triggered the aggregation of aS, which is associated with a high resistance to the proteinase K (PK) digestion of both human and murine aS, a major hallmark of the disease-associated prion protein. In addition, PMCA was also able to trigger the aggregation of murine aS in C57Bl/6 mouse brains after seeding with sick M83 mouse brains. Here, we show that intracerebral inoculations of M83 mice with C57Bl/6-PMCA samples strikingly shortens the incubation period before the typical paralysis that develops in this transgenic model, demonstrating the pathogenicity of PMCA-aggregated murine aS. In the hind brain regions of these sick M83 mice containing lesions with an accumulation of aS phosphorylated at serine 129, aS also showed a high PK resistance in the N-terminal part of the protein. In contrast to M83 mice, old APPxM83 mice co-expressing human mutated amyloid precursor and presenilin 1 proteins were seen to have an aggregation of aS, especially in the cerebral cortex, hippocampus and striatum, which also contained the highest load of aS phosphorylated at serine 129. This was proven by three techniques: a Western blot analysis of PK-resistant aS; an ELISA detection of aS aggregates; or the identification of aggregates of aS using immunohistochemical analyses of cytoplasmic/neuritic aS deposits. The results obtained with the D37A6 antibody suggest a higher involvement of murine aS in APPxM83 mice than in M83 mice. Our study used novel tools for the molecular study of synucleinopathies, which highlight similarities with the molecular mechanisms involved in prion diseases.
Collapse
Affiliation(s)
- Dominique Bétemps
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Jean-Noël Arsac
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Simon Nicot
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Inserm, Etablissement Français Du Sang, 34493 Montpellier, France; (S.N.); (M.B.); (L.B.-O.); (C.M.); (D.B.)
| | - Dominique Canal
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Habiba Tlili
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Maxime Belondrade
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Inserm, Etablissement Français Du Sang, 34493 Montpellier, France; (S.N.); (M.B.); (L.B.-O.); (C.M.); (D.B.)
| | - Eric Morignat
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Jérémy Verchère
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Damien Gaillard
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Lilian Bruyère-Ostells
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Inserm, Etablissement Français Du Sang, 34493 Montpellier, France; (S.N.); (M.B.); (L.B.-O.); (C.M.); (D.B.)
| | - Charly Mayran
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Inserm, Etablissement Français Du Sang, 34493 Montpellier, France; (S.N.); (M.B.); (L.B.-O.); (C.M.); (D.B.)
| | - Latifa Lakhdar
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| | - Daisy Bougard
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Inserm, Etablissement Français Du Sang, 34493 Montpellier, France; (S.N.); (M.B.); (L.B.-O.); (C.M.); (D.B.)
| | - Thierry Baron
- ANSES (French Agency for Food, Environmental and Occupational Health & Safety), University of Lyon, 69364 Lyon, France; (D.B.); (J.-N.A.); (D.C.); (H.T.); (E.M.); (J.V.); (D.G.); (L.L.)
| |
Collapse
|